Onychomycosis Drug Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Onychomycosis is a fungal disease or infection of the nail. It may look like white or yellow nail discoloration, separation of the nail from the nail bed, and thickening of the nail. It is more commonly seen in adults. Onychomycosis is also known as tinea unguium and accounts one-third of fungal skin infections.

MARKET DYNAMICS

The onychomycosis drug market growth is estimated to grow due to the increasing prevalence of onychomycosis, and growing awareness about the toenail infections. The growing product offering and generic production of the pharmaceutical across the world are likely to serve vital growth opportunities during the forecast period.

MARKET SCOPE

The "Onychomycosis Drug Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Onychomycosis drug market with detailed market segmentation by, type, drug type, and distribution channel. The Onychomycosis drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Onychomycosis drug market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Onychomycosis drug market is segmented based on type, drug type, and distribution channel. Based on type, the market is classified as distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis, candida onychomycosis, and others. Based on drug type, the market is classified as prescribed, and OTC. And based on distribution channel, the market is segmented as hospital and retail pharmacies, and online distribution.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Onychomycosis drug market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America (SCAM). The Onychomycosis drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Onychomycosis drug market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Onychomycosis drug market in these regions.

MARKET PLAYERS

The report covers key developments in the Onychomycosis drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Onychomycosis drug market are anticipated to have lucrative growth opportunities in the future with the rising demand for Onychomycosis drug market in the global market. Below mentioned is the list of few companies engaged in the Onychomycosis drug market.

The report also includes the profiles of key players in Onychomycosis drug market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•   Novartis AG
  
•   Galderma Laboratories
  
•   Bausch Health Sciences
  
•   Moberg Pharma AB
  
•   Medimetriks Pharmaceuticals, Inc.
  
•   Merz Pharma
  
•   Kaken Pharmaceutical Co., Ltd
  
•   Taro Pharmaceuticals Industries Ltd
  
•   GlaxoSmithKline plc
  
•   Johnson and Johnson Services, Inc.
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Onychomycosis Drug Report Scope